Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Aadi Bioscience Inc. (AADI) Insider Trading Activity
Healthcare • Biotechnology • 70 employees
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Total Value
$10,989,788.95
Total Shares
4,594,357
Average Trade Value
$1,098,978.90
Most Active Insider
Castelein Caley
Total Activity: $3,998,400
Largest Single Transaction
$3,998,400
by Castelein Caley on Mar 4, 2025
30-Day Activity
4 Transactions
Volume: 4,577,000 shares
Value: $10,984,800
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Mar 4, 2025 | 1,250,000 | $3,000,000 | 1,250,000 (+100.0%) | Grant | ||
| Mar 4, 2025 | 1,666,000 | $3,998,400 | 2,165,998 (+76.9%) | Grant | ||
|
See Remarks
|
Mar 4, 2025 | 100,000 | $240,000 | 202,853 (+49.3%) | Grant | |
| Mar 4, 2025 | 1,561,000 | $3,746,400 | 3,410,402 (+45.8%) | Grant | ||
|
See Remarks
|
Mar 3, 2025 | 2,147 | $5,045 | 102,853 (-2.1%) | Sale | |
|
Chief Executive Officer
|
Mar 3, 2025 | 5,690 | $13,372 | 33,429 (-17.0%) | Sale | |
|
Chief Financial Officer
|
Mar 3, 2025 | 2,806 | $6,594 | 23,944 (-11.7%) | Sale | |
|
Chief Executive Officer
|
Mar 1, 2025 | 16,250 | $10,000 | 39,119 (+41.5%) | Exercise/Conversion | |
|
See Remarks
|
Mar 1, 2025 | 5,000 | $10,000 | 105,000 (+4.8%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Mar 1, 2025 | 6,750 | $10,000 | 26,750 (+25.2%) | Exercise/Conversion |